Because of the benefit of cetuximab for KRAS-variant patients, the KRAS-variant was previously evaluated in the RTOG 0522 HNSCC trial, to determine the impact of cetuximab in combination with radiation and chemotherapy for KRAS-variant patients. This evidence concerns the gene KRAS and head and neck squamous cell carcinoma.